Cornerstone Therapeutics
Cary
About Cornerstone Therapeutics
Cornerstone Therapeutics is a specialty pharmaceutical company focused on developing, acquiring, and commercializing products for the respiratory, hospital and related specialty markets. Key elements of the Company's strategy are to focus on identifying therapeutic niches within respiratory, hospital and related specialty markets to leverage existing business and create new opportunities; promote the Company's current products to high prescribing physicians through the Company's respiratory sales force and to hospital-based healthcare professionals through the Company's hospital sales force; license or acquire rights to existing patent- or trade secret-protected, branded products, which can be promoted through the same channels to generate on-going high-value earnings streams; advance the Company's development projects and further build a robust pipeline; and generate revenues by marketing approved generic products through the Company's wholly owned subsidiary, Aristos Pharmaceuticals, Inc.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $30.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jul 2012)
- Ticker: nasdaq:CRTX
- Website: crtx.com
- Phone: 9196786537
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/cornerstone-therapeutics-831508 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.